Protox Therapeutics has announced the enrollment and successful dosing of the first patient in a Phase I clinical study evaluating their lead drug, PRX302, to treat localized recurrent prostate cancer. PRX302 is a targeted prodrug that turns into a potent anticancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 destroys the cells by punching holes in the cell membrane.
In preclinical studies, PRX302 has been shown to selectively and potently kill PSA-producing cells without harming adjacent healthy tissues or organs. PRX302 has the potential to address the unmet needs of millions of men suffering from localized prostate cancer and enlarged prostates.